Konus-Wind and Helicon-Coronas-F Observations of Solar Flares

Results of solar flare observations obtained in the Konus-Wind experiment from November, 1994 to December, 2013 and in the Helicon Coronas-F experiment during its operation from 2001 to 2005, are presented. For the periods indicated Konus-Wind detected in the trigger mode 834 solar flares, and Helicon-Coronas-F detected more than 300 solar flares. A description of the instruments and data processing techniques are given. As an example, the analysis of the spectral evolution of the flares SOL2012-11-08T02:19 (M 1.7) and SOL2002-03-10T01:34 (C5.1) is made with the Konus-Wind data and the flare SOL2003-10-26T06:11 (X1.2) is analyzed in the 2.223 MeV deuterium line with the Helicon-Coronas-F data.Comment: Published version. A list of the Konus-Wind solar flare triggers and figures of their time profiles are available at http://www.ioffe.ru/LEA/Solar

KW-Sun: The Konus-Wind Solar Flare Database in Hard X-ray and Soft Gamma-ray Ranges

We present a database of solar flares registered by the Konus-Wind instrument during more than 27 years of operation, from 1994 November to now (2022 June). The constantly updated database (hereafter KW-Sun) contains over 1000 events detected in the instrument's triggered mode and is accessible online at http://www.ioffe.ru/LEA/kwsun/. For each flare, the database provides time-resolved energy spectra in energy range from ~20 keV to ~15 MeV in FITS format along with count rate light curves in three wide energy bands G1 (~20-80 keV), G2 (~80-300 keV), and G3 (~300-1200 keV) with high time resolution (down to 16 ms) in ASCII and IDL SAV formats. This article focuses on the instrument capabilities in the context of solar observations, the structure of the KW-Sun data and their intended usage. The presented homogeneous data set obtained in the broad energy range with high temporal resolution during more than two full solar cycles is beneficial for both statistical and case studies as well as a source of context data for solar flare research.Comment: 10 pages, 6 figures, 1 table. Accepted for publication in ApJ

Notes for genera: basal clades of Fungi (including Aphelidiomycota, Basidiobolomycota, Blastocladiomycota, Calcarisporiellomycota, Caulochytriomycota, Chytridiomycota, Entomophthoromycota, Glomeromycota, Kickxellomycota, Monoblepharomycota, Mortierellomycota, Mucoromycota, Neocallimastigomycota, Olpidiomycota, Rozellomycota and Zoopagomycota)

Compared to the higher fungi (Dikarya), taxonomic and evolutionary studies on the basal clades of fungi are fewer in number. Thus, the generic boundaries and higher ranks in the basal clades of fungi are poorly known. Recent DNA based taxonomic studies have provided reliable and accurate information. It is therefore necessary to compile all available information since basal clades genera lack updated checklists or outlines. Recently, Tedersoo et al. (MycoKeys 13:1--20, 2016) accepted Aphelidiomycota and Rozellomycota in Fungal clade. Thus, we regard both these phyla as members in Kingdom Fungi. We accept 16 phyla in basal clades viz. Aphelidiomycota, Basidiobolomycota, Blastocladiomycota, Calcarisporiellomycota, Caulochytriomycota, Chytridiomycota, Entomophthoromycota, Glomeromycota, Kickxellomycota, Monoblepharomycota, Mortierellomycota, Mucoromycota, Neocallimastigomycota, Olpidiomycota, Rozellomycota and Zoopagomycota. Thus, 611 genera in 153 families, 43 orders and 18 classes are provided with details of classification, synonyms, life modes, distribution, recent literature and genomic data. Moreover, Catenariaceae Couch is proposed to be conserved, Cladochytriales Mozl.-Standr. is emended and the family Nephridiophagaceae is introduced

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS